• Immuneering flagged new analyses from its atebimetinib pancreatic cancer program, with results scheduled for presentation at AACR on Sept. 26, 2026.
• The work extends earlier disclosed clinical findings in first-line patients, focusing on treatment effects on body mass and tumor shrinkage.
• The updated assessment links those changes to overall survival, positioning a dual mechanism as a potential differentiator versus standard approaches.
• The presentation centers on atebimetinib combined with modified gemcitabine and nab-paclitaxel in pancreatic ductal adenocarcinoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100730PRIMZONEFULLFEED9824239) on September 10, 2026, and is solely responsible for the information contained therein.